Combinations for the detection and differentiation of viral meningitis-associated pathogens

By employing multiplex fluorescent PCR analysis and specific primer-probe combinations, the challenge of detecting viral meningitis pathogens has been solved, enabling highly sensitive rapid diagnosis and accurate differentiation, thus supporting clinical treatment.

CN118932113BActive Publication Date: 2026-11-10XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411065387.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2026-11-10
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

Current technologies struggle to quickly and accurately distinguish and detect the various pathogens that cause viral meningitis, leading to prolonged clinical diagnosis time and impacting the selection of treatment options.

Method used

Multiplex fluorescent PCR analysis, using specific upstream and downstream primer and probe combinations, can simultaneously detect and distinguish pathogens such as Arungshan virus, novel Bunyavirus, rabies virus, echovirus, measles virus, and Japanese encephalitis virus in a single-tube reaction system, and can be performed in conjunction with a fluorescent PCR instrument.

Benefits of technology

It achieves rapid and accurate detection with high sensitivity (100 copies/mL), providing sufficient diagnostic evidence, shortening the clinical diagnosis time, and supporting targeted treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932113B_ABST
    Figure CN118932113B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of molecular biology detection, specifically relating to compositions and applications for the detection and differentiation of viral meningitis-related pathogens, including herpes simplex virus type 1 / 2 (HSV 1 / 2), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), human herpesvirus type 6 (HHV6), enterovirus (EV), Aaronshan virus (ALSV), novel Bunyavirus (SFTSV), rabies virus (RV), echovirus (ECHOV), measles virus (MeV), and Japanese encephalitis virus (JEV). Furthermore, the compositions of this invention exhibit higher detection sensitivity, reaching 100 copies / mL, resulting in more accurate detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of molecular biology detection, specifically relating to compositions and uses for the detection and differentiation of viral meningitis-related pathogens, including herpes simplex virus type 1 / 2 (HSV 1 / 2), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), human herpesvirus type 6 (HHV6), enterovirus (EV), Aaronshan virus (ALSV), novel Bunyavirus (SFTSV), rabies virus (RV), echovirus (ECHOV), measles virus (MeV), and Japanese encephalitis virus (JEV). Background Technology

[0002] Herpes simplex virus (HSV) is a typical example of herpesviruses. It is an enveloped double-stranded DNA virus that can cause a variety of diseases in humans, such as gingivostomatitis, keratoconjunctivitis, encephalitis, genital infections, and neonatal infections. Based on antigenic differences, it can be divided into two serotypes: HSV-1 and HSV-2. Severe infections can cause dangerous diseases such as sporadic encephalitis.

[0003] Human cytomegalovirus (HCMV), also known as human herpesvirus 5, is a double-stranded DNA virus. HCMV infection can manifest as asymptomatic, systemic symptoms, or invasive disease. In immunocompetent individuals, the virus can remain latent in the host for life after initial infection. Reactivation can occur when the host's immune function is compromised, leading to severe illness. The central nervous system is a common site of HCMV infection in immunocompetent individuals.

[0004] Epstein-Barr virus (EBV), also known as human herpesvirus 4, is the only lymphofollicular DNA virus in the γ subfamily of the Herpesviridae family that can cause human infection. It is commonly differentiated into types A and B based on differences in EBNA2 gene expression. Clinical symptoms vary in severity and presentation, with different systemic infections exhibiting corresponding clinical characteristics. EBV is one of the common pathogens causing viral infections of the central nervous system in children. Adult EBV meningoencephalitis is relatively rare; it is an infectious disease caused by EBV infection, resulting in acute inflammation of the meninges and brain parenchyma, clinically characterized by fever, headache, and meningeal irritation signs.

[0005] Varicella-zoster virus (VZV), also known as human herpesvirus-3 (HHV3), is a double-stranded DNA virus belonging to the alpha-herpesvirus subfamily of the herpesviridae family. It is neuroinvasive, and under natural conditions, humans are the only known host for VZV. Primary infection with VZV causes chickenpox. The virus then remains latent in the ganglia of the cranial nerves, dorsal root ganglia, and autonomic nerves. Reactivation can lead to shingles and can also cause central nervous system (CNS) infections, including meningitis and encephalitis. Epidemiological studies show that since the introduction of live attenuated VZV vaccines, the incidence of chickenpox has significantly decreased, but VZV-related CNS complications are more common and diverse than before.

[0006] Human herpesvirus 6 (HHV6) is a double-stranded DNA virus belonging to the family Herpesviridae, subfamily Betaherpesvirinae. Based on differences in antigenicity, host range, restriction endonuclease patterns, and gene structure among HHV6 isolates, this virus is divided into two types: HHV6A and HHV6B. HHV6 can cause roseola infantum and is associated with neurological disorders. Most newborns acquire specific anti-HHV6 antibodies from their mothers. As the child grows, the titer of maternal antibodies decreases, and the primary infection rate gradually increases, peaking between 6 and 9 months of age.

[0007] Enterovirus (EV) is an RNA virus belonging to the genus Enterovirus in the family Picornaviridae. Enteroviruses are one of the main viruses causing viral encephalitis in my country, primarily affecting children. Epidemiological outbreaks mainly occur in summer and autumn, and are generally sporadic, with large-scale outbreaks being rare. Clinical manifestations in infected individuals range from mild symptoms such as fatigue, weakness, and low-grade fever to severe cases involving systemic infection and damage to vital organs such as the brain and spinal cord.

[0008] Alonshan virus (ALSV) is an RNA virus belonging to the Flaviviridae family and the Jingmenvirus genus. ALSV is caused by infection through tick bites. The main clinical symptoms include fever, fatigue, headache, nausea, altered consciousness, myalgia / arthralgia, lethargy, and rash. The disease is known as "Alonshan fever".

[0009] The novel Bunyavirus (SFTSV), also known as Severe Fever with Thrombocytopenia Syndrome Virus, is a new RNA virus belonging to the genus *Sphingovirus* in the family Bunyaviridae. It is primarily transmitted by ticks and can cause influenza-like or dengue-like illnesses, hemorrhagic fever, and encephalitis in humans.

[0010] Rabies virus (RV) is an RNA virus belonging to the family Rhabdoviridae and the genus Rabiesvirus. The main pathological changes in infected individuals are acute diffuse encephalomyelitis, particularly severe in the dorsal root ganglia and spinal cord segments corresponding to the bite site, the hippocampus, medulla oblongata, pons, and cerebellum. The brain parenchyma shows congestion, edema, and microhemorrhagic changes. Microscopically, nonspecific degeneration and inflammatory changes are visible, such as neuronal vacuolation, hyaline degeneration and chromatin degradation, and perivascular mononuclear cell infiltration.

[0011] Echovirus (ECHOV) is a subclass of enterovirus in the family Parvoviridae. Its morphology, structure, and physicochemical properties are similar to those of poliovirus and Coxsackievirus. It most commonly infects the central nervous system and clinically presents with symptoms such as fever, headache, nausea, vomiting, diarrhea, drowsiness, altered consciousness, decreased attention, poor concentration, memory loss, coma, seizures, and somatic disorders. In addition, it may also present with focal manifestations such as hemisensory disturbance, hemiplegia, and focal neurological deficits.

[0012] Measles virus (MeV) is an RNA virus belonging to the Paramyxoviridae family and the Measlesvirus genus. Subacute sclerosing panencephalitits (SSPE) is a delayed complication of acute measles infection, mainly characterized by progressive decline in brain function; it is a severe condition with a poor prognosis.

[0013] Japanese encephalitis virus (JEV) is an RNA virus belonging to the family Bronchiviridae and the genus Flaviviridae. It is primarily transmitted by mosquitoes or blood-sucking insects. After a mosquito carrying the JEV bites a human, the virus first multiplies in mononuclear macrophages, then enters the bloodstream, triggering an immune response. Antibodies bind to viral antigens and deposit in the brain parenchyma and vascular endothelial cells, activating complement and causing immune damage, mainly manifested as high fever, altered consciousness, convulsions, respiratory failure, and meningeal irritation signs.

[0014] Because viral encephalitis is caused by a wide variety of pathogens with diverse transmission routes, extensive spread, and high infectivity, it is difficult to distinguish the pathogens based solely on clinical manifestations and signs. Furthermore, the treatment regimens differ depending on the pathogen causing the viral encephalitis. Therefore, there is a need in this field for a product that can easily and rapidly detect these pathogens with high sensitivity and specificity, providing clinicians with sufficient and rapid diagnostic evidence to rule out different pathogens, shortening the time required for diagnosis, and accelerating the implementation of treatment measures. Summary of the Invention

[0015] In view of this, in a first aspect, the present invention provides a composition for detecting and differentiating viral meningitis-associated pathogens, comprising a first nucleic acid composition, wherein,

[0016] The first nucleic acid composition includes upstream and downstream primers and probes for detecting at least four of the following pathogens:

[0017] The upstream and downstream primers and probes for detecting Arunshan virus are shown in SEQ ID NO:1-3;

[0018] The upstream and downstream primers and probes for detecting novel Bunyaviruses are shown in SEQ ID NO:4-6;

[0019] The upstream and downstream primers and probes for detecting rabies virus are shown in SEQ ID NO:7-9;

[0020] The upstream and downstream primers and probes for detecting echovirus are shown in SEQ ID NO:10-12;

[0021] For example, the upstream and downstream primers and probes for detecting measles virus shown in SEQ ID NO:13-15; or

[0022] The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NO:16-18.

[0023] The combined detection composition provided by this invention primarily utilizes multiplex fluorescent PCR analysis to detect and differentiate viral meningitis-related pathogens by detecting different sites. This allows for the simultaneous detection and differentiation of at least four pathogens—Arunsun virus, novel Bunyavirus, rabies virus, echovirus, measles virus, and Japanese encephalitis virus—in a single-tube reaction system, providing targeted strategies for subsequent treatment. Furthermore, the composition of this invention offers higher detection sensitivity, reaching 100 copies / mL, resulting in more accurate detection and providing clinicians with sufficient and rapid diagnostic evidence, shortening the time required for patient diagnosis and accelerating the implementation of treatment measures.

[0024] Furthermore, the present invention provides a composition for detecting and differentiating viral meningitis-associated pathogens, comprising a first nucleic acid composition, wherein,

[0025] The first nucleic acid composition comprises:

[0026] The upstream and downstream primers and probes for detecting Arunsan virus, as shown in SEQ ID NO:1-3; and

[0027] Use upstream and downstream primers and probes to detect at least three of the following pathogens:

[0028] The upstream and downstream primers and probes for detecting novel Bunyaviruses are shown in SEQ ID NO:4-6;

[0029] The upstream and downstream primers and probes for detecting rabies virus are shown in SEQ ID NO:7-9;

[0030] The upstream and downstream primers and probes for detecting echovirus are shown in SEQ ID NO:10-12;

[0031] For example, the upstream and downstream primers and probes for detecting measles virus shown in SEQ ID NO:13-15; or

[0032] The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NO:16-18.

[0033] Furthermore, the present invention provides a composition for detecting and differentiating viral meningitis-associated pathogens, comprising a first nucleic acid composition, wherein,

[0034] The first nucleic acid composition includes upstream and downstream primers and probes for detecting the following pathogens:

[0035] The upstream and downstream primers and probes for detecting Arunshan virus are shown in SEQ ID NO:1-3;

[0036] The upstream and downstream primers and probes for detecting novel Bunyaviruses are shown in SEQ ID NO:4-6;

[0037] The upstream and downstream primers and probes for detecting rabies virus are shown in SEQ ID NO:7-9;

[0038] The upstream and downstream primers and probes for detecting echovirus are shown in SEQ ID NO:10-12;

[0039] The upstream and downstream primers and probes for detecting measles virus, as shown in SEQ ID NO:13-15; and

[0040] The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NO:16-18.

[0041] Furthermore, the composition of the present invention further includes: a second nucleic acid composition, wherein the second nucleic acid composition comprises upstream and downstream primers and probes for detecting at least four of the following pathogens:

[0042] The upstream and downstream primers and probes for detecting EB virus are shown in SEQ ID NO:19-21;

[0043] The upstream and downstream primers and probes for detecting varicella-zoster virus are shown in SEQ ID NO:22-24;

[0044] The upstream and downstream primers and probes for detecting human cytomegalovirus are shown in SEQ ID NO:25-27;

[0045] The upstream and downstream primers and probes for detecting human herpesvirus type 6 are shown in SEQ ID NO:28-30;

[0046] As shown in SEQ ID NO:31-33, upstream and downstream primers and probes for detecting herpes simplex virus type 1 / 2; or

[0047] Upstream and downstream primers and probes for detecting enteroviruses, as shown in SEQ ID NO:34-36.

[0048] Furthermore, the composition of the present invention further includes: a second nucleic acid composition, wherein the second nucleic acid composition comprises upstream and downstream primers and probes for detecting the following pathogens:

[0049] The upstream and downstream primers and probes for detecting EB virus are shown in SEQ ID NO:19-21;

[0050] The upstream and downstream primers and probes for detecting varicella-zoster virus are shown in SEQ ID NO:22-24;

[0051] The upstream and downstream primers and probes for detecting human cytomegalovirus are shown in SEQ ID NO:25-27;

[0052] The upstream and downstream primers and probes for detecting human herpesvirus type 6 are shown in SEQ ID NO:28-30;

[0053] The upstream and downstream primers and probes for detecting herpes simplex virus type 1 / 2, as shown in SEQ ID NO:31-33; and

[0054] Upstream and downstream primers and probes for detecting enteroviruses, as shown in SEQ ID NO:34-36.

[0055] Furthermore, the composition includes upstream and downstream primers and probes for detecting an internal standard.

[0056] In some specific implementation schemes, the internal control is a human internal control gene. In one specific implementation scheme, the internal control is a human housekeeping gene.

[0057] Furthermore, the fluorescent groups of the probes for detecting different pathogens in the first nucleic acid composition of the present invention are different from each other and do not interfere with each other.

[0058] Furthermore, in the second nucleic acid composition of the present invention, the fluorescent groups of the probes for detecting different pathogens are different from each other and do not interfere with each other.

[0059] In this article, "different and non-interfering" means that each probe in the composition uses a different fluorescent group, and they do not affect each other's detection; that is, different channels can be used for detection. For example, ATTO425, Quasar705, FAM, HEX, ROX, CY5, and CY5.5 can be used. These groups have different absorbance values, and different channels can be selected, so they will not interfere with each other.

[0060] Furthermore, in some embodiments, the composition of the present invention may simultaneously include one or more pairs of the primer and probe pairs described above. In the present invention, a "pair" refers to a mutually matched upstream and downstream primer and probe for detecting a target.

[0061] Each nucleic acid composition of the present invention can be arbitrarily combined to detect any combination of the six corresponding targets. Those skilled in the art can combine them as needed to determine which targets to detect, i.e., by combining the primers and probes corresponding to the target targets. All such combinations are included in the present invention.

[0062] For example, it may include any 5 pairs of the above 6 pairs of primers and probes, any 4 pairs of the above 6 pairs of primers and probes, any 3 pairs of the above 6 pairs of primers and probes, any 2 pairs of the above 6 pairs of primers and probes, or any 1 pair of the above 6 pairs of primers and probes.

[0063] In some specific embodiments, the compositions of the present invention are used for fluorescent PCR.

[0064] In one specific implementation, the fluorescent reporter group of the probe for Arongshan virus is FAM; the fluorescent reporter group of the probe for novel Bunyavirus is HXE; the fluorescent reporter group of the probe for rabies virus is ROX; the fluorescent reporter group of the probe for echovirus is CY5; the fluorescent reporter group of the probe for measles virus is ATTO 425; and the fluorescent reporter group of the probe for Japanese encephalitis virus is Quasar 705.

[0065] In one specific implementation, the fluorescent reporter group for the EB virus probe is FAM; the fluorescent reporter group for the varicella-zoster virus probe is HXE; the fluorescent reporter group for the human cytomegalovirus probe is ROX; the fluorescent reporter group for the human herpesvirus 6 probe is CY5; the fluorescent reporter group for the herpes simplex virus 1 / 2 probe is ATTO425; and the fluorescent reporter group for the enterovirus probe is Quasar 705.

[0066] Furthermore, the 3' end of the probe also has a non-fluorescent quencher.

[0067] Furthermore, the 3' end of the probe also has a quenching group, such as MGB, Dabcyl BHQ-0, BHQ1, BHQ2, or BHQ3.

[0068] Furthermore, the amount of a single primer in the composition is 0.2–0.5 μM; the amount of a single probe in the composition is 0.1–0.2 μM.

[0069] In one specific embodiment, each component of the composition of the present invention is contained in a separate package.

[0070] In one specific embodiment, the components of the composition of the present invention are contained in the same package.

[0071] Furthermore, the components of the composition of the present invention exist in a mixed form.

[0072] Secondly, the present invention provides the use of the above-described composition of the present invention in the preparation of a kit for detecting, differentiating, and distinguishing viral meningitis-associated pathogens.

[0073] Thirdly, the present invention provides a kit for detecting and differentiating viral meningitis-associated pathogens, the kit comprising the composition of the present invention as described above.

[0074] Furthermore, the kit also includes negative and positive controls.

[0075] In one specific implementation, the negative control is at least one of DEPC H2O, physiological saline, and internal standard gene. The positive control is at least one of the pseudovirus or fragment gene of the virus described in this invention.

[0076] Furthermore, the kit also includes nucleic acid amplification reagents.

[0077] Furthermore, the amplification reagents include dNTPs (U)s, PCR buffer, reverse transcriptase, DNA polymerase, UNG enzyme, and Mg. 2+ At least one of them.

[0078] Furthermore, the kit also includes: nucleic acid release reagent and nucleic acid extraction reagent.

[0079] Furthermore, the concentration of the DNA polymerase is 3 U / reaction to 15 U / reaction, for example, the DNA polymerase can be Taq polymerase; the concentration of the reverse transcriptase is 4 U / reaction to 12 U / reaction, for example, the reverse transcriptase can be Neoscript RT enzyme; and the concentration of the UNG enzyme is 0.4 U to 2 U / reaction.

[0080] In one specific embodiment, the kit of the present invention includes: Taq enzyme, reverse transcriptase, UNG enzyme, Mg2+, dNTP(U)s, primers, probes and PCR buffer.

[0081] PCR buffer consists of components such as Tris-HCl, KCl, and Triton X-100. The total volume of a single PCR reaction tube is generally 20 μl to 200 μl.

[0082] Fourthly, a method for detecting and differentiating pathogens associated with viral meningitis is provided, the method comprising the following steps:

[0083] 1) Extract nucleic acid from the sample to be tested;

[0084] 2) Perform quantitative real-time PCR on the nucleic acid obtained in step 1) using the composition of the present invention as described above or the kit of the present invention as described above;

[0085] 3) Obtain and analyze the results.

[0086] In this invention, the sample used for detection can be serum, blood, cerebrospinal fluid, etc., but is not limited to these.

[0087] Furthermore, the reaction conditions for the quantitative real-time PCR are as follows:

[0088] cDNA reverse transcription and UNG enzyme reaction, temperature 50-65℃, time 2-5 minutes, 1 cycle; cDNA pre-denaturation, temperature 90-99℃, time 5-120 seconds, 1 cycle; denaturation, temperature 94℃, time 5-20 seconds; annealing, temperature 55℃-60℃, time 10-60 seconds, 30-50 cycles, fluorescence collection.

[0089] In one specific implementation, a method is provided for detecting and differentiating viral meningitis-associated pathogens for non-diagnostic purposes, the method comprising the following steps:

[0090] 1) Extract nucleic acid from the sample to be tested;

[0091] 2) Perform quantitative real-time PCR on the nucleic acid obtained in step 1) using the composition or kit of the present invention as described above;

[0092] 3) Obtain and analyze the results.

[0093] Furthermore, the reaction conditions for the quantitative real-time PCR are as follows:

[0094] cDNA reverse transcription and UNG enzyme reaction, temperature 50-65℃, time 2-5 minutes, 1 cycle; cDNA pre-denaturation, temperature 90-99℃, time 5-120 seconds, 1 cycle; denaturation, temperature 95℃, time 5-20 seconds; annealing, temperature 55℃-60℃, time 10-60 seconds, 30-50 cycles, fluorescence collection.

[0095] In one specific embodiment, a composition is provided for use in preparing a composition for detecting and differentiating viral meningitis-associated pathogens, the use of which detects the following steps:

[0096] 1) Extract nucleic acid from the sample to be tested;

[0097] 2) Perform quantitative real-time PCR on the nucleic acid obtained in step 1) using the composition or kit of the present invention as described above;

[0098] 3) Obtain and analyze the results.

[0099] Furthermore, the reaction conditions for the quantitative real-time PCR are as follows:

[0100] cDNA reverse transcription and UNG enzyme reaction, temperature 50-65℃, time 2-5 minutes, 1 cycle; cDNA pre-denaturation, temperature 90-99℃, time 5-120 seconds, 1 cycle; denaturation, temperature 94℃, time 5-20 seconds; annealing, temperature 55℃-60℃, time 10-60 seconds, 30-50 cycles, fluorescence collection. Attached Figure Description

[0101] Figures 1-4 The graph shows the detection results of different sample combinations using the composition of the present invention.

[0102] Figures 5-16 The sensitivity results of the compositions of the present invention are shown in the figure (for Alungshan virus, novel Bunyavirus, rabies virus, echovirus, measles virus, Japanese encephalitis virus, EB virus, varicella-zoster virus, human cytomegalovirus, human herpesvirus 6, herpes simplex virus 1 / 2, and enterovirus, respectively).

[0103] Figure 17 This is a diagram showing the specificity results of the first nucleic acid composition of the present invention;

[0104] Figure 18 This is a diagram showing the specificity results of the second nucleic acid composition of the present invention. Detailed Implementation

[0105] The present invention will be described in detail below with reference to specific implementation schemes and embodiments, thereby making the advantages and various effects of the present invention more clearly apparent. Those skilled in the art should understand that these specific implementation schemes and embodiments are for illustrative purposes only and are not intended to limit the present invention.

[0106] Example 1: Primers and probes used in this invention

[0107] Table 1

[0108]

[0109]

[0110] Note: R is a degenerate base of A and G.

[0111] Among them, the fluorescent reporter group of the probe for Arunsan virus is FAM; the fluorescent reporter group of the probe for novel Bunyavirus is HXE; the fluorescent reporter group of the probe for rabies virus is ROX; the fluorescent reporter group of the probe for echovirus is CY5; the fluorescent reporter group of the probe for measles virus is ATTO 425; and the fluorescent reporter group of the probe for Japanese encephalitis virus is Quasar 705.

[0112] The fluorescent reporter group for the EB virus probe is FAM; the fluorescent reporter group for the varicella-zoster virus probe is HXE; the fluorescent reporter group for the human cytomegalovirus probe is ROX; the fluorescent reporter group for the human herpesvirus 6 probe is CY5; the fluorescent reporter group for the herpes simplex virus 1 / 2 probe is ATTO 425; and the fluorescent reporter group for the enterovirus probe is Quasar 705.

[0113] Example 2: Method for detecting and differentiating pathogens associated with viral meningitis

[0114] The sample used in this invention is cerebrospinal fluid. The real-time fluorescence PCR reaction system is prepared according to Table 2 below. Based on the number of samples to be tested, positive controls, and negative controls, take the corresponding amounts of the first nucleic acid composition reaction solution and enzyme mixture in proportion (38 μL / person of the first nucleic acid composition reaction solution + 2 μL / person of the enzyme mixture), mix thoroughly to form the first nucleic acid composition reaction system, centrifuge at 2000 rpm for 10 seconds, and set aside for later use.

[0115] Take the appropriate amounts of the second nucleic acid composition reaction solution and enzyme mixture according to the ratio (38 μL / person for the second nucleic acid composition reaction solution + 2 μL / person for the enzyme mixture), mix them thoroughly to form the second nucleic acid composition reaction system, centrifuge at 2000 rpm for 10 seconds and set aside.

[0116] Take 200 μL of the test sample, negative control, and positive control into a 1.5 mL centrifuge tube, and perform nucleic acid extraction using the nucleic acid extraction or purification reagent from Sansure Biotech Inc. according to its instructions. Add 10 μL each of the processed sample, negative control, and positive control to their respective 0.2 mL PCR reaction tubes, add 40 μL of PCR mixture to each tube, and cap the tubes.

[0117] Table 2

[0118]

[0119]

[0120] Preparation of enzyme mixture:

[0121] The enzyme mixture consisted of Neoscript RT reverse transcriptase, UNG enzyme, and H-Taq enzyme. H-Taq enzyme (5 U / μL), Neoscript RT enzyme (40 U / μL), and UNG enzyme (2 U / μL) were mixed in a specific ratio (each person's dose consisted of 1.5 μL H-Taq enzyme, 0.3 μL Neoscript RT enzyme, and 0.2 μL UNG enzyme). The PCR amplification program was set as shown in Table 3 below:

[0122] Table 3

[0123]

[0124] If the sample shows obvious S-shaped amplification curves in the FAM, HEX, ROX, CY5, Atto425, and Quasar705 channels, and the Ct value is ≤40, it is judged as positive; if the sample shows no amplification curves (No Ct) or the Ct value is >40 in the FAM, HEX, ROX, CY5, 425, and 705 channels, it is judged as negative; as shown in Table 4.

[0125] Table 4. Interpretation of Test Results

[0126]

[0127]

[0128] Example 3: Detection results of test samples of the composition of the present invention

[0129] The primers and probes shown in Example 1 were used to verify samples of the first nucleic acid composition involving Arongshan virus, novel Bunyavirus, rabies virus, echovirus, measles virus, and Japanese encephalitis virus, according to the method in Example 2. The results showed that the composition of the present invention can detect and distinguish any combination of the above pathogens. For example, the composition of the present invention can detect and distinguish pathogen combinations:

[0130] Arlongshan virus, novel Bunyavirus, measles virus, Japanese encephalitis virus (JE virus) Figure 1 );

[0131] Arlongshan virus, novel Bunyavirus, rabies virus, echovirus, measles virus ( Figure 2 );

[0132] Arlongshan virus, novel Bunyavirus, rabies virus, echovirus, measles virus, Japanese encephalitis virus (JE virus) Figure 3 These figures demonstrate that the first nucleic acid composition of the present invention can amplify any six targets in a single PCR, and can be distinguished using a 6-channel PCR instrument.

[0133] Furthermore, the herpes simplex virus types 1 / 2 (HSV 1 / 2), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), human herpesvirus type 6 (HHV6), and enterovirus (EV) involved in the second nucleic acid composition were validated, specifically as follows: Figure 4 As shown, the second nucleic acid composition of the present invention can amplify the above-mentioned six targets in a single PCR, and can be distinguished using a 6-channel PCR instrument.

[0134] Example 4: Sensitivity of the composition of the present invention

[0135] Using the first and second nucleic acid compositions from Example 1 of this invention, LOD (sensitivity) detection was performed on each target to simulate clinical samples, and multiplex PCR detection was performed on a real-time PCR instrument. Results Figures 5-16 As shown, this indicates that each channel can still accurately detect samples as low as 100 copies / mL, demonstrating that the sensitivity of the composition of the present invention is 100 copies / mL.

[0136] Example 5: Specificity of the composition of the present invention

[0137] The composition of this invention showed no cross-reactivity with common pathogens and other pathogens with similar infection symptoms (such as yellow fever virus, mumps virus, Zika virus, chikungunya virus, adenovirus, human parvovirus, West Nile virus, tick-borne encephalitis virus, rubella virus, etc.). Results are as follows... Figure 17 and 18 As shown, the compositions of the present invention have excellent specificity.

[0138] Example 6: Anti-interference properties of the composition of the present invention

[0139] Analysis of the composition of Example 2 with added interfering substances showed that certain concentrations of potential PCR inhibitors / interfering substances such as dexamethasone, beclomethasone, mometasone, zanamivir, cefotaxime hydrochloride, histamine hydrochloride, azithromycin, tobramycin, ribavirin, mupirocin, fluticasone, budesonide, triamcinolone, heme, purified mucin, and anhydrous ethanol had no significant effect on this kit. The amplification results of the PCR reaction solution in the presence of infectious substances are shown in Table 5 (first nucleic acid composition) and Table 6 (second nucleic acid composition).

[0140] Table 5

[0141]

[0142] Table 6

[0143]

[0144]

Claims

1. A composition for detecting and differentiating viral meningitis-associated pathogens, comprising a first nucleic acid composition, wherein, The first nucleic acid composition includes upstream and downstream primers and probes for detecting at least four of the following pathogens: The upstream and downstream primers and probes for detecting Arunshan virus are shown in SEQ ID NO:1~3; The upstream and downstream primers and probes for detecting novel Bunyaviruses are shown in SEQ ID NO:4~6; The upstream and downstream primers and probes for detecting rabies virus are shown in SEQ ID NO:7~9; The upstream and downstream primers and probes for detecting echovirus are shown in SEQ ID NO:10~12; For example, the upstream and downstream primers and probes for detecting measles virus shown in SEQ ID NO:13~15; or The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NO:16~18.

2. The composition according to claim 1, characterized in that, The composition comprises a first nucleic acid composition, wherein... The first nucleic acid composition comprises: The upstream and downstream primers and probes for detecting the Arunshan virus, as shown in SEQ ID NO:1~3; and Use upstream and downstream primers and probes to detect at least three of the following pathogens: As shown in SEQ ID NO:4~6, upstream and downstream primers and probes for detecting novel Bunyavirus; The upstream and downstream primers and probes for detecting rabies virus are shown in SEQ ID NO:7~9; The upstream and downstream primers and probes for detecting echovirus are shown in SEQ ID NO:10~12; For example, the upstream and downstream primers and probes for detecting measles virus shown in SEQ ID NO:13~15; or The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NO:16~18.

3. The composition according to claim 1 or 2, characterized in that, The composition further includes: a second nucleic acid composition, wherein, The second nucleic acid composition includes upstream and downstream primers and probes for detecting at least four of the following pathogens: The upstream and downstream primers and probes for detecting EB virus are shown in SEQ ID NO:19~21; The upstream and downstream primers and probes for detecting varicella-zoster virus are shown in SEQ ID NO:22~24; The upstream and downstream primers and probes for detecting human cytomegalovirus are shown in SEQ ID NO:25~27; The upstream and downstream primers and probes for detecting human herpesvirus 6 are shown in SEQ ID NO:28~30; As shown in SEQ ID NO:31~33, upstream and downstream primers and probes for detecting herpes simplex virus type 1 / 2; or The upstream and downstream primers and probes for detecting enteroviruses are shown in SEQ ID NO:34~36.

4. The composition according to claim 3, characterized in that, The composition further includes: a second nucleic acid composition, wherein, The second nucleic acid composition includes upstream and downstream primers and probes for detecting the following pathogens: The upstream and downstream primers and probes for detecting EB virus are shown in SEQ ID NO:19~21; The upstream and downstream primers and probes for detecting varicella-zoster virus are shown in SEQ ID NO:22~24; The upstream and downstream primers and probes for detecting human cytomegalovirus are shown in SEQ ID NO:25~27; The upstream and downstream primers and probes for detecting human herpesvirus 6 are shown in SEQ ID NO:28~30; The upstream and downstream primers and probes for detecting herpes simplex virus type 1 / 2, as shown in SEQ ID NO:31~33; and The upstream and downstream primers and probes for detecting enteroviruses are shown in SEQ ID NO:34~36.

5. The composition according to claim 4, characterized in that, The fluorescent groups of the probes for detecting different pathogens in the first nucleic acid composition are different from each other and do not interfere with each other, and / or the fluorescent groups of the probes for detecting different pathogens in the second nucleic acid composition are different from each other and do not interfere with each other.

6. The composition according to any one of claims 1 to 5, characterized in that, The components of the nucleic acid composition exist in a mixed form.

7. Use of the composition of any one of claims 1 to 6 in the preparation of a kit for detecting and differentiating viral meningitis-associated pathogens.

8. A kit for detecting and differentiating viral meningitis-associated pathogens, said kit comprising the composition as described in any one of claims 1 to 6.

9. The reagent kit according to claim 8, characterized in that, The kit also includes at least one of nucleic acid release reagent, nucleic acid extraction reagent, and nucleic acid amplification reagent.

10. A method for detecting and differentiating viral meningitis-associated pathogens for non-diagnostic purposes, the method comprising the following steps: 1) Extract nucleic acid from the sample to be tested; 2) Perform quantitative real-time PCR analysis on the nucleic acid obtained in step 1) using the composition as described in any one of claims 1 to 6 or the kit as described in claim 8 or 9; 3) Obtain and analyze the results.

Citation Information

Patent Citations

  • Primer group and kit for multiple PCR detection of encephalitis and meningitis related viruses

    CN106399586A

  • System and kit for detecting multiple genes of central nervous system infection pathogens

    CN118406803A